Increasing prevalence of
gastrointestinal disorders and H. pylori-associated infections is expected to
propel the market growth
The market
for sucralfate in the United States is likely to be driven by the rising
incidence of stomach ulcers caused by the use of nonsteroidal anti-inflammatory
medications (NSAIDs) and H. pylori infection. According to a study published in
2016 by the Deccan College of Medical Sciences, Helicobacter pylori is
responsible for 95 percent of duodenal ulcers and 70% of stomach ulcers. NSAID
use is also linked to roughly 14-25 percent of stomach and duodenal ulcers,
according to the same study.
The rising prevalence
of peptic ulcers is likely to fuel market expansion. According to research
published in the ScienceDirect Journal in 2016, duodenal ulcers are the most
frequent type of peptic ulcer, with a prevalence of roughly 6% to 12% in the
United States.
Increasing collaboration and
acquisition strategies adopted by market players is expected to bolster the
market growth
Due to
increased inorganic expansion tactics such as collaboration and acquisitions by
market competitors, the U.S.
sucralfate market is predicted to rise significantly. For example,
Forest Laboratories, Inc., a fully integrated specialty pharmaceutical firm,
purchased Aptalis Pharma Inc., a specialty pharmaceutical company and maker of
Carafate, in 2014. TPG, a worldwide private investment group, agreed to sell
Aptalis to Forest for US$ 2.9 billion in cash.
The market
is predicted to develop due to an increase in the number of applications and
uses of sucralfate in the United States. According to a paper published in
April 2018 by the American Broncho Esophagological Association, sucralfate
combined with honey aids in the treatment of esophageal damage in infants and
children. Button Batteries (BB), little disc-shaped batteries typically seen in
toys, have been linked to esophageal harm in newborns and toddlers.
Furthermore,
the rising frequency of GERD and Helicobacter pylori infection is likely to
boost the sucralfate market in the United States throughout the forecast
period. According to the National Institute of Diabetes and Digestive and
Kidney Diseases (NIDDK), the prevalence of GERD in the United States in 2014
was found to be between 15% and 30%. In the United States, the frequency of
Helicobacter pylori positive infection is 35.6 percent, according to statistics
published in the American Gastroenterological Association (AGA) Journal in
2017.
Key Players
Teva
Pharmaceutical Industries Ltd., Allergan plc, Vertice Pharma LLC, and
Pharmaceutical Associates Inc. are among the major sucralfate market players in
the United States.
Comments
Post a Comment